MedTrace Logo

Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy Volunteers

NCT03644108 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-02-28

Study results available
· View outcomes & findings →

Summary

Evaluate the Pharmacokinetics of Mucinex® 600 mg Extended-Release Bi-Layer Tablet in Normal Healthy Subjects

Conditions

  • Healthy Subjects

Interventions

DRUG

Mucinex® ER 600 mg

Single dose of Mucinex® 600 mg ER Bi-Layer tablet

Sponsors & Collaborators

  • Reckitt Benckiser Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-04
Primary Completion
2009-06-15
Completion
2009-06-15
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03644108 on ClinicalTrials.gov